Mast Cell Treatment in Post-tick Bite Illness (PTBI)

This is a Phase II double-blinded study to assess the safety, tolerability, and feasibility of the mast cell stabilizing medications ketotifen and cromolyn compared to participants receiving standard of care treatment with fexofenadine alone in participants who have persistent symptoms of mast cell activation following a documented tick-borne illness (Ehrlichiosis, Rocky Mountain Spotted Fever, Alpha-gal Syndrome).

NCT Number	NCT07526558
Lead Sponsor	University of North Carolina, Chapel Hill Collaborators: Columbia University
Conditions	Post-tick Bite Illness, Mast Cell Stabilizer
Enrollment	50 participants
Start Date	2026-04-30
Primary Completion	2027-01 (estimated)
Study Completion	2027-01 (estimated)
Updated on ClinicalTrials.gov	2026-04-13